Home › NDC Lookup › Ingredients › Methenamine Hippurate › 50742-0142-01
⚪image loading
(from DailyMed)

METHENAMINE HIPPURATE 1 g Tablet, 100-count

by Ingenus Pharmaceuticals, LLC · 100 TABLET in 1 BOTTLE (50742-142-01)
NDC 50742-0142-01
🏷️ FDA NDC (as labeled) 50742-142-01 billing pads the product segment with a zero
Rx only Generic On market Non-controlled
🗂️ Data synced Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

🆔 Identity & classification

FDA NDC (as labeled) 50742-142-01
Product NDC 50742-142
11-digit billing NDC 50742014201
NCPDP billing unit EA — each (per item)
RxCUI 992150
UNII M329791L57
UPC 0350742142019
Application # ANDA210068
SPL Set ID 4412d667-63f6-427e-a5c6-376a0e1e172d
DEA schedule Non-controlled
Marketing category ANDA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2020-12-18
Route ORAL
Dosage form TABLET
Substance METHENAMINE HIPPURATE
GPI-14 16800020200305
GPI class Methenamine Hippurate
GCN Seq No 009457
GCN 41980
HICL code 004101
Ingredient (HICL) Methenamine Hippurate
HIC1 code W
Therapeutic class — broad (HIC1) Anti-Infecting Agents
HIC2 code W2
Therapeutic class — intermediate (HIC2) Antibacterials
HIC3 code W2G
Therapeutic class — specific (HIC3) Antibiotic, Antibacterial, Misc.
AHFS code 08:36.00.00
AHFS class Urinary Anti-Infectives
FDB label name METHENAMINE HIPP 1 GM TABLET
FDB brand name Methenamine Hippurate
Legend status F — Federal legend — prescription drug or device
TE code (Orange Book) AB · RLD · RS
Why two NDCs? The FDA registers this code as 50742-142-01 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 50742-0142-01. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

🏷️ RxNorm drug class

This medicine belongs to the Other antibacterials class.

Drug family (ATC) Other antibacterials
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

🏭 Manufacturer & labeler

LabelerIngenus Pharmaceuticals, LLC
Application holderINGENUS PHARMACEUTICALS LLC
FDA applicationANDA210068 (ANDA)
Labeler code50742
First marketedDec 2020
Product typeHuman Prescription Drug
Portfolio139 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

🩺 Clinical

Label name METHENAMINE HIPP 1 GM TABLET Ingredient Methenamine Hippurate
📗 Our plain-language guide HelloPharmacist
  • That's a great question. Methenamine isn't used to clear an active infection — it's used to prevent another one from taking hold. Once your other antibiotic has done that job, meth...
  • Why do I need to take methenamine if my infection is already gone?
  • Yes, it actually does. Methenamine only converts into its active antibacterial form in acidic urine. Foods and medications that make your urine more alkaline — less acidic — can re...
  • Does it matter what I eat or drink while I'm on this medication?
📖 Read our full Methenamine guide →
7
Nutrient depletion considerations

Methenamine Hippurate may be associated with lower levels of 7 nutrients — worth a chat with your pharmacist, not a cause for alarm.

🧪 Full Methenamine Hippurate nutrient depletion report →
An association is not a deficiency. Educational only — don't start or stop anything without professional guidance.
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

🧪 Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • UNII H77VEI93A8
    A synthetic yellow dye used to color medications. It helps identify the drug and make it visually distinctive, with no effect on how the medicine works.
  • UNII 70097M6I30
    Magnesium stearate is a salt made from magnesium and stearic acid, a fatty substance. It's used in tablets and capsules as a lubricant and glidant to help ingredients flow smoothly during manufacturing and prevent sticking.
  • UNII FZ989GH94E
    Povidone is a synthetic polymer made from a plastic-like material. It acts as a binder to hold tablet ingredients together and as a disintegrant to help the tablet break apart in your stomach so the medicine can be absorbed.
  • UNII SB8ZUX40TY
    Saccharin sodium is an artificial sweetener made from saccharin salt. It's added to medicines to improve taste, especially in liquid formulations for children or bitter drugs.
  • UNII ETJ7Z6XBU4
    Silicon dioxide is a naturally occurring mineral used as a glidant and anti-caking agent. It helps powder ingredients flow smoothly and prevents clumping during manufacturing and storage.

5 inactive ingredients listed in the exact product block matched to this NDC.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed — ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

💲 Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer eaPer package
Retail pharmacies payNADAC · weekly $0.311 $31.14 / 100 tablets
Medicaid paysCMS SDUD · 12 mo $0.5432 $54.32 / 100 tablets
Medicare drug plans payPart D · Q2 2026 $0.5951 $59.51 / 100 tablets
NADAC price history (per ea) — tap or hover for the price & month
Dec 2021 Jul 2022 Dec 2025 Aug 2026 $0.870 $0.307
▼ Down 64% over the last 24 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

🔁 Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Methenamine Hippurate 1000 mg 42571-0332-01 Micro 100 tablets $0.311 AB Availability likely —
Methenamine Hippurate 1 g 47781-0577-01 Alvogen 100 tablets $0.311 AB Availability likely —
Methenamine Hippurate 1000 mg 50268-0549-15 AvPAK 50 tablets $0.311 AB Availability likely —
Methenamine Hippurate 1 gthis 50742-0142-01 Ingenus 100 tablets $0.311 AB Availability likely —
Methenamine Hippurate 1 g 59746-0797-01 Jubilant 100 tablets $0.311 AB Availability likely —
Methenamine Hippurate 1000 mg 60687-0694-21 American 30 tablets $0.311 AB Availability likely —
Methenamine Hippurate 1 g 65862-0782-01 Aurobindo 100 tablets $0.311 AB Availability likely —
Methenamine hippurate 1 g 72578-0175-01 Viona 100 tablets $0.311 AB Availability likely —
Methenamine Hippurate 1 g 72603-0816-01 NorthStar 100 tablets $0.311 AB Availability likely —
Methenamine Hippurate 1 g 51407-0880-01 Golden 100 tablets — AB FDA listed —
Methenamine Hippurate 1 g 70685-0050-01 Esjay 100 tablets — AB Discontinued —
Methenamine hippurate 1 g 70771-1919-01 Zydus 100 tablets — AB FDA listed —
Methenamine Hippurate 1 g 70954-0959-10 ANI 100 tablets — AB FDA listed —
About this product: this is a generic version of the medicine. FDA equivalence ratings are shown when available, and other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

⏳ Availability & generic status

🏛️
2020
On the market since
Dec 2020
📍
2026
Currently FDA-listed
6 years listed
🔓
·
Generic on the market
this product is a generic
✅This is a generic drug

This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

🗺️ Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for 50742-0142-01, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q4 2025 · 4 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
13.1K
Units reimbursed last 4 qtrs
830.8K
Gross reimbursed last 4 qtrs
$451.3K
Avg / prescription
$34.50
Avg / unit
$0.5432
Latest quarter Q4 2025
3KRx
Medicaid pays / ea
$0.5432
gross reimbursed
vs
NADAC / ea
$0.3114
acquisition cost
=
Spread
+$0.2318
+74% vs cost
What Medicaid paid per ea (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
53% FFS 47% MCO
Fee-for-service · 6,896 Rx Managed care · 6,186 Rx
State Medicaid map
Alaska: no data reported AK Maine: 1,080 units · 77.4 per 100k residents ME Washington: 15,355 units · 197 per 100k residents WA Idaho: 7,112 units · 362 per 100k residents ID Montana: 2,890 units · 255 per 100k residents MT North Dakota: 1,642 units · 210 per 100k residents ND Minnesota: 18,540 units · 323 per 100k residents MN Wisconsin: 16,073 units · 272 per 100k residents WI Michigan: 29,456 units · 293 per 100k residents MI New York: 48,317 units · 247 per 100k residents NY Vermont: 1,860 units · 287 per 100k residents VT New Hampshire: no data reported NH Oregon: 1,222 units · 28.9 per 100k residents OR Nevada: 13,370 units · 419 per 100k residents NV Wyoming: no data reported WY South Dakota: no data reported SD Iowa: no data reported IA Illinois: 11,418 units · 91.0 per 100k residents IL Indiana: 5,647 units · 82.3 per 100k residents IN Ohio: 24,932 units · 212 per 100k residents OH Pennsylvania: 25,259 units · 195 per 100k residents PA New Jersey: 9,224 units · 99.3 per 100k residents NJ Massachusetts: 15,919 units · 227 per 100k residents MA California: 284,226 units · 729 per 100k residents CA Utah: 660 units · 19.3 per 100k residents UT Colorado: 8,933 units · 152 per 100k residents CO Nebraska: no data reported NE Missouri: 11,381 units · 184 per 100k residents MO Kentucky: 23,373 units · 516 per 100k residents KY West Virginia: 4,110 units · 232 per 100k residents WV Virginia: 13,616 units · 156 per 100k residents VA Maryland: 13,216 units · 214 per 100k residents MD Connecticut: 7,292 units · 202 per 100k residents CT Rhode Island: 1,620 units · 148 per 100k residents RI Arizona: 22,984 units · 309 per 100k residents AZ New Mexico: no data reported NM Kansas: 6,993 units · 238 per 100k residents KS Arkansas: no data reported AR Tennessee: 4,636 units · 65.1 per 100k residents TN North Carolina: 9,942 units · 91.8 per 100k residents NC South Carolina: 7,035 units · 131 per 100k residents SC Delaware: no data reported DE Oklahoma: 2,110 units · 52.1 per 100k residents OK Louisiana: 4,982 units · 109 per 100k residents LA Mississippi: 5,019 units · 171 per 100k residents MS Alabama: 8,774 units · 172 per 100k residents AL Georgia: no data reported GA D.C.: no data reported DC Hawaii: no data reported HI Texas: 54,134 units · 177 per 100k residents TX Florida: 86,439 units · 382 per 100k residents FL
Units reimbursed · per 100k residents
19.3729
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 California 729 /100k
2 Kentucky 516 /100k
3 Nevada 419 /100k
4 Florida 382 /100k
5 Idaho 362 /100k
6 Minnesota 323 /100k
7 Arizona 309 /100k
8 Michigan 293 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

📊 Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Methenamine Hippurate — the program that covers self-administered drugs. 7 manufacturers.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Methenamine Hippurate. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$18.08M
Claims incl. refills
301K
Beneficiaries
166.6K
Spend / beneficiary
$108.53
Spend / claim
$60.07
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.

🔬 Reported adverse events (FAERS)

Read carefully: FAERS reports are voluntary and unverified. Counts are not incidence, do not establish causation, are subject to reporting bias, and cannot be used to compare one drug to another. Shown for signal context only. Reports for Methenamine Hippurate — the ingredient across all brands.

Top reported reactions

Urinary Tract Infection163
Diarrhoea81
Nausea80
Fall74
Fatigue74
Headache65
Dizziness60

Reporter sex

1,210 reports

Serious outcomes

Death75
Disabling29
Reports over time (by year) — tap or hover for the count & year
2019 2021 2023 2026 180 72
Most recent year is provisional (FAERS lags ~3 months).
Where does this data come from?
Adverse-event reports from the FDA Adverse Event Reporting System (FAERS) via openFDA. FAERS reports are voluntary and unverified — counts are not incidence and don’t establish causation.

📦 Packaging — all sizes for this product

Package NDCDescription Marketing startStatus
50742-0142-01 You're viewing this 100 TABLET in 1 BOTTLE (50742-142-01) 2020-12-18 Active

📄 Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage ⏱️ Dosage and Administration ⛔ Contraindications ⚠️ Warnings 🤒 Adverse Reactions 🧓 Geriatric Use 📦 How Supplied / Storage and Handling 📋 Description 💬 Information for Patients
🎯 Indications and Usage 117 words ▾

INDICATIONS Methenamine hippurate tablets are indicated for prophylactic or suppressive treatment of frequently recurring urinary tract infections when long-term therapy is considered necessary. This drug should only be used after eradication of the infection by other appropriate antimicrobial agents. To reduce the development of drug-resistant bacteria and maintain the effectiveness of methenamine hippurate and other antibacterial drugs, methenamine hippurate tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.

When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

⏱️ Dosage and Administration 95 words ▾

DOSAGE AND ADMINISTRATION 1 tablet (1.0 g) twice daily (morning and night) for adults and pediatric patients over 12 years of age. 1/2 to 1 tablet (0.5 to 1.0 g) twice daily (morning and night) for pediatric patients 6 to 12 years of age. Since the antibacterial activity of methenamine hippurate tablets, USP is greater in acid urine, restriction of alkalinizing foods and medications is desirable.

If necessary, as indicated by urinary pH and clinical response, supplemental acidification of the urine should be instituted. The efficacy of therapy should be monitored by repeated urine cultures.

⛔ Contraindications 40 words ▾

CONTRAINDICATIONS Methenamine hippurate tablets are contraindicated in patients with renal insufficiency, severe hepatic insufficiency, or severe dehydration. Methenamine preparations should not be given to patients taking sulfonamides because some sulfonamides may form an insoluble precipitate with formaldehyde in the urine.

⚠️ Warnings 25 words ▾

WARNINGS Large doses of methenamine (8 grams daily for 3 to 4 weeks) have caused bladder irritation, painful and frequent micturition, albuminuria, and gross hematuria.

🤒 Adverse Reactions 43 words ▾

ADVERSE REACTIONS Minor adverse reactions have been reported in less than 3.5% of patients treated. These reactions have included nausea, upset stomach, dysuria and rash. To report SUSPECTED ADVERSE REACTIONS, contact Ingenus Pharmaceuticals, LLC at 1-877-748-1970 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .

🧓 Geriatric Use 100 words ▾

Geriatric Use Clinical studies of methenamine hippurate tablets did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal or cardiac function, and of concomitant disease or other drug therapy.

Methenamine hippurate tablets are contraindicated in patients with renal insufficiency and severe hepatic insufficiency (see CONTRAINDICATIONS).

📦 How Supplied / Storage and Handling 66 words ▾

HOW SUPPLIED Peach colored, capsule shaped, biconvex tablets debossed with "I" and "7"on one side and scoreline on two sides, free from mottled surface in bottles of 100 (NDC 50742- 142-01). Store at 25°C (77°F); excursions permitted to 15–30°C (59–86°F) [see USP Controlled Room Temperature]. Dispense in well-closed, light-resistant container with child-resistant closure.

Manufactured for: Ingenus Pharmaceuticals, LLC Orlando, FL 32811 Rx Only 553502 Revised: 01/2023

📋 Description 55 words ▾

DESCRIPTION Methenamine Hippurate Tablets, USP is a urinary tract antiseptic drug. Each peach color, capsule-shaped bi-convex tablet contains 1 g methenamine hippurate which is the hippuric acid salt of methenamine (hexamethylene tetramine). The tablet also contains inactive ingredients: FD&C Yellow No. 6, Magnesium Stearate, Colloidal Silicon Dioxide, Povidone, and Saccharin Sodium. Structural Formula: Structural Formula:

💬 Information for Patients 114 words ▾

Information for Patients Patients should be counseled that antibacterial drugs including methenamine hippurate tablets should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When methenamine hippurate tablets are prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed.

Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by methenamine hippurate tablets or other antibacterial drugs in the future.

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗
← 50742-0118-08 · Ingenus 50742-0175-01 · Ingenus →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.